

PETER GUNZBURG CHAIRMAN

INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) announces that David Williams will step down as Chairman effective today, 18 December 2025. Peter Gunzburg has been elected to the role of Chairman from that date.

Commenting on his appointment, Mr Gunzburg said: "I would like to thank David Williams for his leadership and helping INOVIQ reach a point where it can now approach the next stage of its product development properly funded and resourced. With funding for our next-generation exosome-based platforms, we are well positioned to achieve significant milestones that will create value for patients, partners, and shareholders."

Authorised for release by Company Secretary, Mark Edwards.

FURTHER INFORMATION:

Peter Gunzburg
Chairman
E peter.gunzburg@gmail.com
M +61 412 927 773

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics to transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inovig.com.

